跳至主要内容
临床试验/NL-OMON41424
NL-OMON41424招募中2 期

PANFIRE - Pilot-study: Non-thermal ablation using Irreversible Electroporation (IRE) to treat locally advanced pancreatic carcinoma - a phase I clinical study - Pilot-study: Treatment of LAPC with Irreversible Electroporation (IRE)

Vrije Universiteit Medisch Centrum0 个研究点目标入组 40 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
招募中
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • Screening must be performed no longer than 2 weeks prior to study inclusion. Subjects are eligible if they meet the following criteria:;* Histologic or cytologic confirmation of primary pancreatic carcinoma;
  • * Radiologic confirmation of unresectable pancreatic carcinoma without distant metastases by at least ceCT of chest and abdomen, performed maximum 2 weeks prior to the procedure;
  • * Maximum tumor diameter * 5 cm;
  • * Age * 18 years;
  • * ASA-classificaton 0 * 3;
  • * Life expectancy of at least 12 weeks;
  • * Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to definite inclusion;
  • - Hemoglobin * 5.6 mmol/L;
  • - Absolute neutrophil count (ANC) * 1,500/mm3;
  • - Platelet count * 100*109/l;
  • - Total bilirubine * 1.5 times the upper limit of normal (ULN);
  • - ALT and AST * 2.5 x ULN;
  • - Serum creatinine * 1.5 x ULN or a calculated creatinine clearance * 50 ml/min;
  • - Prothrombin time or INR < 1.5 x ULN;
  • - Activated partial thromboplastin time < 1.25 x ULN (therapeutic anticoagulation therapy is
  • allowed if this treatment can be interrupted as judged by the treating physician);
  • * Written informed consent;

排除标准

  • Subjects who meet the following criteria at the time of screening will be excluded:
  • * Resectable pancreatic adenocarcinoma as discussed by our multidisciplinary hepatobiliary team;
  • * Extrapancreatic metastases;
  • * Successful downstaging after (radio)chemotherapy from previous unresectable/borderline tumor to resectable tumor;
  • * History of epilepsy;
  • * History of cardiac disease:
  • - Congestive heart failure >NYHA class 2;
  • - Active Coronary Artery Disease (defined as myocardial infarction within 6 months prior to
  • screening);
  • - Ventricular cardiac arrhythmias requiring anti-arrhythmic therapy or pacemaker (beta blockers for antihypertensive regimen are permitted);
  • * Uncontrolled hypertension. Blood pressure must be *160/95 mmHg at the time of screening on a stable antihypertensive regimen;
  • * Compromised liver function (e.g. signs of portal hypertension, INR > 1,5 without use of anticoagulants, ascites);
  • * Uncontrolled infections (> grade 2 NCI-CTC version 3.0);
  • * Pregnant or breast-feeding subjects. Women of childbearing potential must have a negative pregnancy test performed within 7 days of the start of treatment;
  • * Immunotherapy * 6 weeks prior to the procedure;
  • * Chemotherapy * 6 weeks prior to the procedure;
  • * Radiotherapy * 6 weeks prior to the procedure;
  • * Concomitant use of anti-convulsive and anti-arrhythmic drugs (other than beta blockers for hypertension);
  • * Allergy to contrast media;
  • * Any implanted stimulation device;
  • * Any condition that is unstable or that could jeopardize the safety of the subject and their compliance in the study

研究者

相似试验